MIT researchers have introduced a new theoretical framework that enables more efficient testing of multiple treatment combinations, potentially accelerating drug development for diseases like cancer or genetic disorders. This approach helps scientists estimate the effects of treatment combinations on groups such as cells, allowing them to gather more accurate data while conducting fewer costly experiments.

For instance, when studying how gene interactions influence cancer cell growth, a biologist may need to apply several treatments simultaneously to target different genes. However, with billions of possible combinations, selecting only a few to test can introduce bias into the results. The new method addresses this challenge by guiding smarter, more balanced selection of treatment combinations.

Figure 1. A Smarter Way to Study Complex Treatment Interactions

In contrast to traditional methods, the new framework allows researchers to design unbiased experiments by assigning all treatments simultaneously and adjusting their application rates to influence outcomes. Figure 1 shows A Smarter Way to Study Complex Treatment Interactions.

MIT researchers provided a theoretical proof for a near-optimal strategy within this framework and validated it through simulations in a multiround experimental setting. Their method consistently reduced the error rate across trials.

This approach could ultimately aid scientists in gaining deeper insights into disease mechanisms and accelerating the development of new treatments for conditions like cancer and genetic disorders.

“We’ve introduced a new concept that can guide future efforts to identify optimal strategies for selecting treatment combinations during each experimental round. We hope this approach will eventually help address important biological questions,” says graduate student Jiaqi Zhang, an Eric and Wendy Schmidt Center Fellow and co-lead author of a paper detailing the experimental design framework.

The paper was co-authored by Divya Shyamal, an MIT undergraduate and co-lead author, and Caroline Uhler, the senior author. Uhler is the Andrew and Erna Viterbi Professor of Engineering in EECS and the MIT Institute for Data, Systems, and Society (IDSS), director of the Eric and Wendy Schmidt Center, and a researcher at MIT’s Laboratory for Information and Decision Systems (LIDS). The team presented their findings at the International Conference on Machine Learning.

Parallel Treatment Strategies

Treatments can interact in complex and unpredictable ways. For example, to determine whether a specific gene influences a disease symptom, a scientist may need to target multiple genes simultaneously. This is typically done through combinatorial perturbations, where several treatments are applied at once to a group of cells.

“These perturbations help map out high-level gene interaction networks, offering insights into how cells function,” explains Jiaqi Zhang.

However, genetic experiments are both expensive and time-consuming, so selecting the most informative treatment combinations is a major challenge due to the enormous number of possibilities. Choosing a limited, preselected subset can introduce bias and lead to incomplete or misleading results.

To overcome this, MIT researchers proposed a probabilistic framework that avoids preselecting fixed treatment sets. Instead, each cell is randomly assigned treatment combinations based on dosage levels specified by the user. These dosage levels function like probabilities—higher dosages increase the likelihood a treatment is applied to more cells, while lower dosages reduce it.

This approach produces less biased data by allowing all possible combinations to be represented in varying proportions. As co-author Divya Shyamal explains, “The question becomes: how do we design these dosages to estimate the outcomes as accurately as possible? That’s where our theory comes in.”

The framework provides a method for optimizing dosage levels to maximize learning about the trait or biological process being studied. After each experimental round, results are fed back into the system, which then updates and adapts the dosage strategy for the next round—refining the process over time.

MIT researchers developed a theoretical framework that optimizes treatment dosages in multiround experiments, even under supply constraints or variable noise [1]. Their method minimized error rates in simulations, outperforming existing approaches. Future work will address unit interference and selection bias, with plans to apply the technique in real-world settings. The study was supported by MIT's Advanced UROP, Apple, NIH, ONR, DOE, the Eric and Wendy Schmidt Center, and a Simons Investigator Award.

References:

1. https://news.mit.edu/2025/more-efficiently-studying-complex-treatment-interactions-0716

Cite this article:

Janani R (2025), A More Efficient Approach to Studying Complex Treatment Interactions, AnaTechMaz, pp. 444